5,6-dihydroxy-2-methylaminotetralin, also known as 2-methylamino-5,6-dihydroxytetralin or 2-Me-5,6-DHT, is a synthetic dopamine agonist. It is a potent and selective agonist at dopamine D2 receptors and is used in research as a tool to study the role of dopamine in various neurological and psychiatric disorders. 5,6-DHT has been shown to have antidepressant, anxiolytic, and antiparkinsonian effects in animal models. Its unique pharmacological profile has led to interest in its potential therapeutic applications for conditions such as depression, anxiety, and Parkinson's disease. However, 5,6-DHT has not been approved for clinical use in humans. Its synthesis involves multiple steps starting from commercially available starting materials. Its effects are mainly attributed to its agonistic activity at dopamine receptors, leading to modulation of dopamine signaling pathways in the brain. Research on 5,6-DHT aims to understand the mechanisms of dopamine receptor signaling and its therapeutic potential in treating neurological and psychiatric conditions.'
5,6-dihydroxy-2-methylaminotetralin: beta2 adrenergic agonist; coronary vasodilator in vivo; cyclic dopamine analog; synonym M-8 refers to HBr; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 38005 |
| SCHEMBL ID | 3829971 |
| MeSH ID | M0067849 |
| Synonym |
|---|
| m-8 |
| L019298 |
| 6-(methylamino)-5,6,7,8-tetrahydronaphthalene-1,2-diol |
| 1,2-naphthalenediol, 5,6,7,8-tetrahydro-6-(methylamino)- |
| 5,6-dihydroxy-2-methylaminotetralin |
| unii-045q4e2k14 |
| 2-n-methylamino-5,6-dihydrotetralin |
| 39478-89-2 |
| 045q4e2k14 , |
| 5,6-dihydroxy-2-(methyl)aminotetralin |
| 2-(methylamino)-5,6-dihydroxy-1,2,3,4-tetrahydronaphthalene |
| 2-n-methylamino-5,6-dihydroxytetralin |
| chf-1024 free base |
| SCHEMBL3829971 |
| Q27247623 |
| DTXSID30960108 |
| AKOS040749975 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The objectives of this study are to develop and validate a population pharmacokinetic model that adequately describes the pharmacokinetics of nelfinavir and its active metabolite M8 in HIV-1-infected children; to define factors involved in the pharmacokinetic variability, which could aid in defining dosing strategies; and to correlate the pharmacokinetics to the treatment response." | ( Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children. Beijnen, JH; Crommentuyn, KM; Huitema, AD; Kuijpers, TW; Mathôt, RA; Scherpbier, HJ, 2006) | 0.33 |
| " A population pharmacokinetic model of nelfinavir and M8 was developed using NONMEM." | ( Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children. Beijnen, JH; Crommentuyn, KM; Huitema, AD; Kuijpers, TW; Mathôt, RA; Scherpbier, HJ, 2006) | 0.33 |
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objectives of this study are to develop and validate a population pharmacokinetic model that adequately describes the pharmacokinetics of nelfinavir and its active metabolite M8 in HIV-1-infected children; to define factors involved in the pharmacokinetic variability, which could aid in defining dosing strategies; and to correlate the pharmacokinetics to the treatment response." | ( Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children. Beijnen, JH; Crommentuyn, KM; Huitema, AD; Kuijpers, TW; Mathôt, RA; Scherpbier, HJ, 2006) | 0.33 |
| " No factors affecting dosing strategies were identified, and no correlation could be demonstrated between the exposure to nelfinavir and M8 and the virologic treatment response." | ( Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children. Beijnen, JH; Crommentuyn, KM; Huitema, AD; Kuijpers, TW; Mathôt, RA; Scherpbier, HJ, 2006) | 0.33 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.78) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||